Avirmax

Avirmax Biopharma Inc. is a clinical-stage biopharmaceutical company based in the San Francisco Bay Area focused on the development of targeted recombinant AAV (rAAV) gene therapies for chronic and age-related degenerative ocular diseases. The company's proprietary engineered capsid platform, AAV.N54, is optimized for superior intravitreal delivery to the macular retina, enabling safe and efficient transgene delivery. Its lead program, ABI-110, has received FDA IND approval and targets wet macular degeneration (wAMD). Avirmax aims to provide gene therapy solutions that are safe, effective, affordable, and accessible.